Pembrolizumab‐induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient. Issue 4 (11th March 2019)

• Record Type: Journal Article
• Authors: Honigman, Anthony D.; Lai, Franics; Elakis, Joshua; Prall, Owen; Goh, Michelle; McCormack, Christopher
• Is Part Of: Clinical case reports. Volume 7:Issue 4(2019)
• Page Start: 773
• Page End: 775
• Publication Date: 2019-03-11
• Subjects: granulomatous panniculitis -- immunotherapy -- PD‐1 inhibitor -- Pembrolizumab; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.2090
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: Pembrolizumab is an immune checkpoint inhibitor with antitumor activity in other organ malignancies. We present this case —demonstrating multiple inflammatory adverse events associated with Pembrolizumab (in a single patient), in order to increase awareness and facilitate earlier identification of the wide‐ranging cutaneous side effects associated with immunotherapy. Abstract : Pembrolizumab is an immune checkpoint inhibitor with antitumor activity in other organ malignancies. We present this case —demonstrating multiple inflammatory adverse events associated with Pembrolizumab (in a single patient), in order to increase awareness and facilitate earlier identification of the wide‐ranging cutaneous side effects associated with immunotherapy.